CAMH will study PEX010, Filament’s botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment VANCOUVER, BC, Feb. 14, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced a second agreement to supply the Centre for…


Previous articleSilo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
Next articleDelix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability